For people living with metabolic fatty liver disease, the question of how far the damage has advanced has long required a tissue sample, an invasive procedure that was often the only route to certainty. A large study spanning Europe and the United States now asks whether a simple blood draw might carry part of that burden. Its answer is mixed in a telling way: the early stages of the illness still resist reliable detection, while the later, scarred stages yield more readily to a single protein in the blood. The promise lies less in replacing the needle entirely than in learning to read the bod
Single Blood Protein TSP2 Outperforms Complex Tests in Flagging Advanced Fatty Liver Scarring
A simple blood protein that performs as well as more elaborate testing
Mark
Why does this study matter beyond the usual promise of a new test?
Mimi
Scale and method. It checked 30 markers and combinations against biopsy results in 1,590 patients, across 37 centers in 13 countries.
Mark
And the standout was a single protein?
Mimi
Thrombospondin-2, a connective tissue protein. Its level in the blood points to fibrosis that carries a risk of becoming cirrhosis.
Luke
Worth being precise, though. It performed well, and it's called one of the most promising markers. That's not the same as replacing biopsy.
Mark
Fair. What about early disease?
Mimi
None of the tests met the study's predetermined threshold for diagnosing early MASLD without significant scarring.
Luke
So the gap is real. The good results are for significant fibrosis and cirrhosis, not for catching disease early.
Mark
Do we know how TSP2 compares with the elastography combinations?
Luke
Not from what's reported here. Several methods did well, but no ranking or numbers are given, so I wouldn't claim TSP2 is the best.
Mimi
The cheap, noninvasive promise is still a future possibility. The source frames it as potential, pending validation.
O Pulso
- Thirty blood tests were pitted against liver biopsies in 1,590 patients, and the field is racing to find a way around the needle.
- No single test or combination could reliably catch fatty liver disease in its early stage, before significant scarring sets in.
- The protein TSP2 emerged as a standout, detecting significant fibrosis and cirrhosis with notable accuracy.
- Elastography-based combinations also performed strongly, offering clinicians more than one route to a noninvasive read.
- Validation is the next hurdle, and if it holds, routine liver checks could move out of specialist clinics and into everyday blood work.
For people living with metabolic fatty liver disease, the question of how far the damage has advanced has long required a tissue sample, an invasive procedure that was often the only route to certainty. A large study spanning Europe and the United States now asks whether a simple blood draw might carry part of that burden. Its answer is mixed in a telling way: the early stages of the illness still resist reliable detection, while the later, scarred stages yield more readily to a single protein in the blood. The promise lies less in replacing the needle entirely than in learning to read the body's quieter signals before they harden into something graver.
For patients with metabolic dysfunction-associated steatotic liver disease, learning how far the illness has progressed has usually meant a liver biopsy. A tissue sample is taken from the organ and examined. It is invasive, and for a long time it was the only way to be sure.
A large European and American study called LITMUS set out to test whether a blood draw could take on some of that work. Across 37 liver centers in 13 countries, researchers compared 30 biomarkers and test combinations against biopsy results in 1,590 patients, using the biopsy as a confirmed reference point.
The early stages of fatty liver disease proved stubbornly hard to catch. None of the tests met the study's predetermined standard for diagnosing disease without significant scarring.
The picture was brighter for advanced disease. Several methods diagnosed significant fibrosis and cirrhosis well, including elaborate combinations that use elastography. But one single protein, thrombospondin-2, stood out. TSP2 is a connective tissue protein whose level in the blood reliably signals scarring that risks progressing to cirrhosis.
The hope is that such tests could one day offer an inexpensive, noninvasive way to check liver health across the general population. Accurate staging guides when treatment should begin and how well it is working. Whether these results survive validation will decide if a simple blood protein can change how often a biopsy is truly needed.
For patients with metabolic dysfunction-associated steatotic liver disease, known as MASLD, finding out how far the illness has progressed has often meant a liver biopsy. A tissue sample is taken from the organ and examined. It is invasive, and until now it has frequently been the only way to be sure.
A large European and American study has now tested whether a blood draw could do part of that job. The study is called LITMUS, short for Liver Investigation: Testing Marker Utility in Steatohepatitis. It set 30 individual biomarkers and test combinations against biopsy results to see how well each could diagnose MASLD and its advanced, progressive form, metabolic dysfunction-associated steatohepatitis, or MASH.
The data behind the comparison is substantial. The researchers analyzed 1,590 patients with MASLD whose disease had been accurately diagnosed by tissue biopsy. Participants were enrolled between 2018 and 2023 at 37 liver centers in 13 countries across Europe and the United States. Because the biopsy results served as the reference, each test could be judged against a confirmed diagnosis.
The findings split into two parts. None of the tests reached the threshold the study had set in advance for diagnosing the early stages of fatty liver disease, meaning disease without significant scarring, or fibrosis. For that early picture, no marker or combination did well enough by the study's own standard.
For more advanced disease, the results were better. Several methods performed very well in diagnosing significant liver fibrosis and cirrhosis. Some were more complex combinations, including ones that involve elastography, a specialized ultrasound technique. But one single marker stood out: thrombospondin-2, or TSP2.
TSP2 is a connective tissue protein. Its concentration in the blood gives reliable indications of fibrotic changes in the liver that carry a risk of progressing to cirrhosis. It is described as one of the most promising blood-based markers for assessing progressive and advanced liver fibrosis and inflammation, the category referred to as MASH at risk.
The broader hope is that newly developed blood tests could eventually offer a noninvasive and inexpensive way to assess liver health in the general population. Reliable staging matters because it guides the decision to start treatment and lets doctors monitor how a patient responds to therapy. The next question is whether these results hold up under validation, since a simple blood protein that performs as well as more elaborate testing would change how often a biopsy is needed.
Citações Notáveis
TSP2 is one of the most promising blood-based markers for assessing progressive and advanced liver fibrosis and inflammation (MASH at risk).— LITMUS study reporting
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Health & Medicine